Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of Tezepelumab

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511730-12-00

Acronym

ESR-21-21168

Enrollment

Registered

2024-05-08

Start date

2024-05-09

Completion date

Unknown

Last updated

2024-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Brief summary

The change, expressed as ratio, in eosinophil cell counts per mm2 from baseline to week-20

Interventions

DRUGPLACEBO

DRUGTEZEPELUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The change, expressed as ratio, in eosinophil cell counts per mm2 from baseline to week-20	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026